X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Gloperba (colchicine) liquid oral solution is a USFDA approved, tubulin inhibitor small molecule drug candidate which is indicated for prophylaxis of gout flares in adults.
Lead Product(s): Colchicine
Therapeutic Area: Rheumatology Product Name: Gloperba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
The net proceeds will be used for the commercialisation of ZTlido® (lidocaine topical system), a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: Ztlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rodman & Renshaw LLC
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 05, 2024
Details:
The net proceeds will be used for the commercialisation of ZTlido® (lidocaine topical system), a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: Ztlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rodman & Renshaw LLC
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Details:
Elyxyb (celecoxib) is a nonsteroidal anti-inflammatory drug that acts as a cyclooxygenase-2 inhibitor. It is indicated for the acute treatment of migraine with or without aura in adults.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
Elyxyb (celecoxib) is a nonsteroidal anti-inflammatory drug with analgesic, anti-inflammatory, and antipyretic properties. Celecoxib inhibits prostaglandin synthesis, primarily via inhibition of COX-2. It is being developed for migrane pain.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2023
Details:
SP-102 (semdexatm) is expected to be administered in up to 3 injections during a 6-month observation period. Completion of enrollment for Lumbosacral Radicular Pain (Sciatica) in the trial is projected to occur in 2025.
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Musculoskeletal Product Name: SP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
The agreement aims for the distribution of Ztlido (lidocaine), a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia, in Kingdom of Saudi Arabia.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: Ztlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Farouk, Maamoun Tamer & Co.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 31, 2023
Details:
SP-103 (lidocaine topical system) 5.4% triple strength formulation for ZTlido®, is being investigated in subjects with moderate to severe acute lower back pain (LBP).
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: SP-103
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
Proceeds from the financing commitment will be used to enhance the launch and commercialization of Scilex’s three FDA-approved non-opioid pain management products, ZTlido (lidocaine), Gloperba (colchicine) and Elyxyb (celecoxib), for the treatment of acute and chronic pain.
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: Ztlido
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: YA II PN
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 21, 2023
Details:
Elyxyb (celecoxib) is a nonsteroidal anti-inflammatory drug with analgesic, anti-inflammatory, and antipyretic properties. Celecoxib inhibits prostaglandin synthesis, primarily via inhibition of COX-2. It is being developed for migrane pain.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
